NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• NewAmsterdam Pharma Company N.V. has received a consensus rating of “Moderate Buy” from ten analysts, with nine recommending to buy the stock and one rating it as a hold.
• The average 12-month price target for NewAmsterdam Pharma among analysts is $41.55, with specific targets ranging from $39.00 to $45.00 from different brokerage firms.
• NewAmsterdam Pharma reported a quarterly earnings beat with an EPS of ($0.15), significantly exceeding consensus estimates, while also achieving a revenue of $19.15 million, well above expectations.

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $41.5455.

Several research analysts have weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, June 4th. They set an "overweight" rating and a $42.00 target price for the company. Stifel Nicolaus initiated coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target on the stock. Needham & Company LLC reissued a "buy" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Wells Fargo & Company initiated coverage on shares of NewAmsterdam Pharma in a research report on Monday, August 25th. They set an "overweight" rating and a $45.00 price target on the stock. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th.

Insider Activity

In related news, COO Douglas F. Kling sold 51,043 shares of the firm's stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $21.10, for a total value of $1,077,007.30. Following the sale, the chief operating officer owned 44,000 shares of the company's stock, valued at $928,400. This trade represents a 53.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James N. Topper bought 2,520 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average cost of $18.43 per share, for a total transaction of $46,443.60. Following the acquisition, the director owned 3,024,873 shares of the company's stock, valued at $55,748,409.39. This represents a 0.08% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 12,835 shares of company stock worth $248,134 and sold 256,881 shares worth $5,445,954. 20.84% of the stock is owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

Hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after purchasing an additional 596 shares in the last quarter. Northern Trust Corp purchased a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth $556,000. Barclays PLC boosted its position in shares of NewAmsterdam Pharma by 120.0% during the 4th quarter. Barclays PLC now owns 16,713 shares of the company's stock worth $429,000 after purchasing an additional 9,117 shares in the last quarter. Arizona State Retirement System purchased a new stake in shares of NewAmsterdam Pharma during the 1st quarter worth $215,000. Finally, California State Teachers Retirement System boosted its position in shares of NewAmsterdam Pharma by 23.5% in the 4th quarter. California State Teachers Retirement System now owns 19,404 shares of the company's stock worth $499,000 after buying an additional 3,694 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Up 1.0%

NAMS stock traded up $0.25 during mid-day trading on Tuesday, hitting $24.88. 1,019,333 shares of the company were exchanged, compared to its average volume of 805,462. The firm has a market capitalization of $2.80 billion, a P/E ratio of -15.36 and a beta of -0.01. The business has a fifty day simple moving average of $22.67 and a 200-day simple moving average of $20.47. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.37. The company had revenue of $19.15 million during the quarter, compared to analyst estimates of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. Research analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.